Cinacalcet is an effective treatment for secondary hyperparathyroidism in patients on dialysis. Until now, no randomized, placebo-controlled, long-term trial has tested this drug in individuals ...
Dr Reddy's Laboratories is recalling over 3.3 lakh bottles of Cinacalcet tablets in the US due to manufacturing issues. The ...
Stocks to watch on Monday, November 4, 2024: Indian bourses are preparing for a negative start on Monday, indicated GIFT ...
During the initial titration phase of up to 16 weeks, patients received increasing dosages of cinacalcet until the serum calcium concentration was <2.5 mmol/l, the highest possible dosage was ...
Cinacalcet (Sensipar ® /Mimpara ®, Amgen Inc., Thousand Oaks, CA), the first-in-class calcimimetic agent approved for treatment of secondary hyperparathyroidism in dialysis patients, is ...
The recall is due to the 'presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit', it added.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback